Clevudine: Difference between revisions

Jump to navigation Jump to search
(Created page with "<div style="float: right;"> thumb|none|400px|This image is provided by the National Library of Medicine.</div> __NOTOC__ {{SI}} {{CMG}} ==Overview==...")
 
No edit summary
Line 1: Line 1:
<div style="float: right;">
<div style="float: right;">
[[File:Clevudine.png|thumb|none|400px|This image is provided by the National Library of Medicine.]]</div>
[[File:Clevudine.png|thumb|none|400px|This image is provided by the National Library of Medicine.]]</div>
__NOTOC__
__NOTOC__
{{SI}}
{{SI}}
{{CMG}}
{{CMG}}
==Overview==
==Overview==
'''Clevudine''' ([[International Nonproprietary Name|INN]]) is an antiviral drug for the treatment of [[hepatitis B]] (HBV). It is already approved for HBV in [[South Korea]] and the [[Philippines]]. It is marketed by Bukwang Pharmaceuticals in South Korea under the tradenames '''Levovir''' and '''Revovir'''.
'''Clevudine''' ([[International Nonproprietary Name|INN]]) is an antiviral drug for the treatment of [[hepatitis B]] (HBV). It is already approved for HBV in [[South Korea]] and the [[Philippines]]. It is marketed by Bukwang Pharmaceuticals in South Korea under the tradenames '''Levovir''' and '''Revovir'''.
Line 17: Line 13:


{{Antivirals}}
{{Antivirals}}
[[Category:Nucleoside analog reverse transcriptase inhibitors]]
[[Category:Pyrimidinediones]]
[[Category:Organofluorides]]
[[Category:Organofluorides]]
[[Category:Arabinosides]]
[[Category:Drug]]
[[Category:Drug]]
{{antiinfective-drug-stub}}

Revision as of 14:29, 7 April 2015

This image is provided by the National Library of Medicine.

WikiDoc Resources for Clevudine

Articles

Most recent articles on Clevudine

Most cited articles on Clevudine

Review articles on Clevudine

Articles on Clevudine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Clevudine

Images of Clevudine

Photos of Clevudine

Podcasts & MP3s on Clevudine

Videos on Clevudine

Evidence Based Medicine

Cochrane Collaboration on Clevudine

Bandolier on Clevudine

TRIP on Clevudine

Clinical Trials

Ongoing Trials on Clevudine at Clinical Trials.gov

Trial results on Clevudine

Clinical Trials on Clevudine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Clevudine

NICE Guidance on Clevudine

NHS PRODIGY Guidance

FDA on Clevudine

CDC on Clevudine

Books

Books on Clevudine

News

Clevudine in the news

Be alerted to news on Clevudine

News trends on Clevudine

Commentary

Blogs on Clevudine

Definitions

Definitions of Clevudine

Patient Resources / Community

Patient resources on Clevudine

Discussion groups on Clevudine

Patient Handouts on Clevudine

Directions to Hospitals Treating Clevudine

Risk calculators and risk factors for Clevudine

Healthcare Provider Resources

Symptoms of Clevudine

Causes & Risk Factors for Clevudine

Diagnostic studies for Clevudine

Treatment of Clevudine

Continuing Medical Education (CME)

CME Programs on Clevudine

International

Clevudine en Espanol

Clevudine en Francais

Business

Clevudine in the Marketplace

Patents on Clevudine

Experimental / Informatics

List of terms related to Clevudine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Clevudine (INN) is an antiviral drug for the treatment of hepatitis B (HBV). It is already approved for HBV in South Korea and the Philippines. It is marketed by Bukwang Pharmaceuticals in South Korea under the tradenames Levovir and Revovir.

Under license from Bukwang, Pharmasset was developing the drug, but its phase III clinical trial (international, multicenter, randomized, double-blind, 96 week QUASH studies) was terminated due to some myopathy cases in patients. It's approval in South Korea was revoked following these findings. It is a nucleoside analog.

References